ethinyl estradiol

English name ethinylestradiol

also known as ethinyloestradiol · EE20 · EE · EE2

Developed for: polycystic ovary syndrome · dysmenorrhea · anovulation · acne · premenstrual dysphoric disorder · infertility disorder · menstrual disorder · premenstrual tension
+40 more
· adenomyosis · depressive disorder · endometrial polyp · endometriosis · hemometra · major depressive disorder · migraine disorder · ovarian endometriosis · pelvis syndrome · premature menopause · primary dysmenorrhea · primary ovarian failure · systemic lupus erythematosus · uterine disorder · amenorrhea · anemia · anorexia nervosa · binge eating disorder · bone remodeling disease · breast cancer · chronic pain syndrome · COVID-19 · cystic fibrosis · endometrial cancer · functional hypothalamic amenorrhea · hidradenitis suppurativa · multiple sclerosis · osteoporosis · ovarian disorder · postpartum depression · pregnancy disorder · sexual disorder · temporomandibular joint disorder · endometrial disorder · female infertility · headache disorder · myocardial ischemia · ovarian cyst · ovarian dysfunction · uterine anomalies
Investigated by: Bayer · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Pfizer · Boehringer Ingelheim · Novo Nordisk A/S
+179 more
· AstraZeneca · Bristol-Myers Squibb · Nobelpharma · Wyeth is now a wholly owned subsidiary of Pfizer · Duramed Research · Eli Lilly and Company · Janssen Research & Development, LLC · GlaxoSmithKline · Population Council · Agile Therapeutics · Massachusetts General Hospital · AbbVie · Laboratorios Andromaco S.A. · Parexel · University of Colorado, Denver · Vertex Pharmaceuticals Incorporated · Warner Chilcott · Amgen · Bio-innova Co., Ltd · Canadian Institutes of Health Research (CIHR) · Celerion · Conselho Nacional de Desenvolvimento Científico e Tecnológico · FHI 360 · Janssen Pharmaceutica N.V., Belgium · Mahidol University · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. · Novartis Pharmaceuticals · Oregon Health and Science University · Penn State University · Purdue University · Society of Family Planning · Teva Branded Pharmaceutical Products R&D, Inc. · Teva Women's Health · United States Agency for International Development (USAID) · University of Palermo · University of Pennsylvania · University of Roma La Sapienza · University of Saskatchewan · University of Virginia · ViiV Healthcare · Achillion, a wholly owned subsidiary of Alexion · Aegerion Pharmaceuticals, Inc. · Ain Shams Maternity Hospital · Alexion Pharmaceuticals, Inc. · Altimmune, Inc. · Anuja Dokras · Aquinox Pharmaceuticals (Canada) Inc. · Assembly Biosciences · Astellas Pharma Global Development, Inc. · Atea Pharmaceuticals, Inc. · Basilea Pharmaceutica International Ltd · Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · Bial - Portela C S.A. · Biogen · Biolab Sanus Farmaceutica · Blueprint Medicines Corporation · Boston Children's Hospital · Bristol Myers Squibb Company (BMS) · CMN "20 de Noviembre" · CONRAD · Centers for Disease Control and Prevention · Chemo Research · Children's Mercy Hospital Kansas City · Chongqing Medical University · Chulalongkorn University · Clinic of Phlebology and Laser Surgery, Chelyabinsk, Russia · Concert Pharmaceuticals · Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. · Covance · Deciphera Pharmaceuticals, LLC · Eastern Virginia Medical School · Ege University · Enanta Pharmaceuticals, Inc · Erasmus Medical Center · all 185 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Evra	—	2002-08-22	europa.eu ↗
Approved	US (FDA)	ESTINYL	—	1943-06-25	fda.gov ↗

Trials 281 · started per year

today

US approved 1943

EU approved 2002

194119421943194419451946194719481949195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 05 trials
Phase 0	NCT07568509	May 2026 → Apr 2027 expected	hypopituitarism, neurohypophyseal diabetes insipidus	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 0	NCT03905941	Aug 2021 → Nov 2024	polycystic ovary syndrome	University of Virginia	Withdrawn	No outcome recorded Stop: Business
Phase 0	NCT04423068	Dec 2020 → Apr 2022	pregnancy disorder	Children's Mercy Hospital Kansas City	Completed	No outcome recorded
Phase 0	NCT03037944	Mar 2016 → Dec 2017	adenomyosis	Ain Shams Maternity Hospital	Unknown	No outcome recorded
Phase 0	NCT02036879	Feb 2014 → Aug 2018	cystic fibrosis	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 1122 trials · 4 met primary
Phase 1	NCT07808060	Sep 2026 → Jun 2027 expected	obesity disorder	Eli Lilly and Company	Recruiting	No outcome recorded
Phase 1	NCT07792408	Sep 2026 → Mar 2027 expected	autosomal dominant polycystic kidney disease	Vertex Pharmaceuticals Incorporated	Recruiting	No outcome recorded
Phase 1	NCT07710729	Jul 2026 → Apr 2027 expected	obesity disorder	Novo Nordisk A/S	Not yet recruiting	No outcome recorded
Phase 1	NCT07340190	Jun 2026 → Mar 2028 expected	cancer	Novartis Pharmaceuticals	Recruiting	No outcome recorded
Phase 1	NCT07539090	Jun → Oct 2026 expected	—	Deciphera Pharmaceuticals, LLC	Recruiting	No outcome recorded
Phase 1	NCT07523711	Apr → Nov 2026 expected	obesity disorder	Amgen	Active not recruiting	No outcome recorded
Phase 1	NCT07525791	Apr 2026 → May 2027 expected	obesity disorder	Novo Nordisk A/S	Active not recruiting	No outcome recorded
Phase 1	NCT07502417	Mar → Jul 2026 overdue	—	AbbVie	Active not recruiting	No outcome recorded
Phase 1	NCT07414784	Feb → Aug 2026	—	AbbVie	Completed	No outcome recorded
Phase 1	NCT07388511	Feb → Apr 2026	—	Blueprint Medicines Corporation	Completed	No outcome recorded
Show all 122 trials opens the full record — a long page
Phase 232 trials · 2 met primary · 2 missed
Phase 2	NCT07010146	Oct 2025 → Dec 2029 expected	bone remodeling disease, functional hypothalamic amenorrhea	University of Virginia	Recruiting	No outcome recorded
Phase 2	NCT07083635	Jul 2025 → Sep 2026 overdue	hemometra, menstrual disorder	Chulalongkorn University	Recruiting	No outcome recorded
Phase 2	NCT05098574	Feb 2023 → Apr 2024	bipolar disorder, premenstrual dysphoric disorder	St. Joseph's Healthcare Hamilton	Completed	No outcome recorded
Phase 2	NCT05360550	Jul 2022 → Jan 2023	—	Lupin Research Inc	Completed	No outcome recorded
Phase 2	NCT04278755	Sep 2020 → May 2022	binge eating disorder, bulimia nervosa	University of North Carolina, Chapel Hill	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT02550977	Sep 2015 → Jul 2016	—	Bayer	Completed	No outcome recorded
Phase 2	NCT01968135	Oct 2013 → Nov 2014	uterine disorder	University of Colorado, Denver	Completed	Met primary
Phase 2	NCT01388491	Oct 2011 → Sep 2012	vascular hemostatic disease	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	Met primary
Phase 2	NCT01310647	Jun 2011 → Dec 2012	ovarian disorder	La Fe Health Research Institute	Completed	Missed primary
Phase 2	NCT01252186	Nov 2010 → Dec 2011	vascular hemostatic disease	Teva Women's Health	Completed	No outcome recorded
Phase 2	NCT01204190	Sep 2010 → Jul 2011	—	Bayer	Completed	No outcome recorded
Phase 2	NCT00896571	Jul 2009 → May 2011	—	Bayer	Completed	No outcome recorded
Phase 2	NCT00933179	Jun 2009 → Sep 2010	—	Bayer	Completed	No outcome recorded
Phase 2	NCT00924560	Jun 2009 → Aug 2012	—	Duramed Research	Completed	No outcome recorded
Phase 2	NCT00915915	Jun 2009 → Apr 2010	anovulation	Bayer	Completed	No outcome recorded
Phase 2	NCT00873483	Apr 2009 → Mar 2010	—	Bayer	Completed	No outcome recorded
Phase 2	NCT00722800	Oct 2008 → Dec 2011	hidradenitis suppurativa	Massachusetts General Hospital	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00729404	Aug 2008 → Feb 2009	anovulation	Bayer	Terminated	No outcome recorded
Phase 2	NCT01250210	Sep 2007 → Feb 2008	anovulation	Agile Therapeutics	Completed	No outcome recorded
Phase 2	NCT00471991	Apr → Dec 2007	—	Bayer	Completed	No outcome recorded
Phase 2	NCT00394771	Oct 2006 → Mar 2008	—	Duramed Research	Completed	No outcome recorded
Phase 2	NCT00338052	Jun 2006 → May 2007	—	Warner Chilcott	Completed	No outcome recorded
Phase 2	NCT00318799	Apr 2006 → May 2007	—	Bayer	Completed	No outcome recorded
Phase 2	NCT00196313	May 2005 → Oct 2008	dysmenorrhea	Duramed Research	Completed	No outcome recorded
Phase 2	NCT00089414	Jul 2004 → Jun 2010	depressive disorder, premenstrual dysphoric disorder	National Institute of Mental Health (NIMH)	Terminated	No outcome recorded
Phase 2	NCT00673686	May 2004 → Feb 2005	—	Bayer	Completed	No outcome recorded
Phase 2	NCT00344383	Nov 2003 → Jul 2004	hemometra	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Completed	No outcome recorded
Phase 2	NCT00213096	Mar 2003 → Feb 2004	—	Population Council	Completed	No outcome recorded
Phase 2	NCT00254189	Dec 2002 → Oct 2004	anovulation	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 2	NCT00151801	May 2002 → Dec 2008	multiple sclerosis	S. Andrea Hospital	Unknown	No outcome recorded
Phase 2	NCT00033358	Feb 2002 → Oct 2007	endometrial cancer	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00320567	? → Apr 2004	osteoporosis	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Completed	Missed primary

Phase 2/34 trials · 1 met primary
Phase 2/3	NCT00511797	Jul 2007 → Jan 2009	dysmenorrhea	Bayer	Completed	Met primary
Phase 2/3	NCT00461305	Feb 2007 → Jan 2009	dysmenorrhea	Bayer	Completed	No outcome recorded
Phase 2/3	NCT00955058	Feb 2007	polycystic ovary syndrome	Shahid Beheshti University	Unknown	No outcome recorded
Phase 2/3	NCT00310791	Apr 2004 → Oct 2009	anorexia nervosa	Boston Children's Hospital	Completed	No outcome recorded
Phase 358 trials · 9 met primary · 1 missed
Phase 3	NCT07714616	May 2027 → May 2029 expected	—	Eurofarma Laboratorios S.A.	Not yet recruiting	No outcome recorded
Phase 3	NCT05139121	Oct 2021 → Jan 2025	—	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT03945513	Dec 2019 → Jun 2023	—	Insud Pharma	Completed	No outcome recorded
Phase 3	NCT04007874	Sep 2019 → Dec 2024	migraine disorder	Leiden University Medical Center	Unknown	No outcome recorded
Phase 3	NCT03843736	Feb 2019 → Jun 2020	polycystic ovary syndrome	Peking Union Medical College Hospital	Unknown	No outcome recorded
Phase 3	NCT03229057	Jan 2018 → Jan 2024	polycystic ovary syndrome	Anuja Dokras	Completed	Missed primary
Phase 3	NCT02922348	Mar 2016 → Dec 2018	primary ovarian failure	University of Pennsylvania	Withdrawn	No outcome recorded
Phase 3	NCT02617537	Jan 2016 → Sep 2017	dysmenorrhea	Bayer	Withdrawn	No outcome recorded
Phase 3	NCT02362711	Feb 2015 → Jan 2017	dysmenorrhea	Nobelpharma	Completed	No outcome recorded
Phase 3	NCT02158572	Aug 2014 → Nov 2016	—	Agile Therapeutics	Completed	No outcome recorded
Phase 3	NCT01892904	Jul 2013 → Jan 2015	dysmenorrhea	Bayer	Completed	No outcome recorded
Phase 3	NCT03359057	Feb → Jul 2013	—	Galeno Desenvolvimento de Pesquisas Clínicas	Completed	No outcome recorded
Phase 3	NCT01697111	Oct 2012 → Mar 2014	endometriosis	Bayer	Completed	Met primary
Phase 3	NCT02021097	Feb 2012 → Feb 2015	—	Regenex Pharmaceutical, China	Unknown	No outcome recorded
Phase 3	NCT01246791	Nov 2010 → May 2011	—	Nobelpharma	Completed	No outcome recorded
Phase 3	NCT01181479	Aug 2010 → Dec 2011	—	Agile Therapeutics	Completed	No outcome recorded
Phase 3	NCT01129102	May 2010 → Apr 2011	dysmenorrhea	Nobelpharma	Completed	Met primary
Phase 3	NCT01044498	Dec 2009 → Feb 2012	rheumatoid arthritis	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00996580	Oct 2009 → Sep 2011	—	Teva Women's Health	Completed	No outcome recorded
Phase 3	NCT00910637	May 2009 → Dec 2010	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00902746	May 2009 → Feb 2012	dysmenorrhea	Nobelpharma	Completed	No outcome recorded
Phase 3	NCT00984789	May 2009 → Sep 2010	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00914693	Apr 2009 → Sep 2011	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00824187	Jan 2009 → Jan 2011	premenstrual dysphoric disorder	Bayer	Completed	No outcome recorded
Phase 3	NCT00818519	Dec 2008 → May 2010	acne	Bayer	Completed	No outcome recorded
Phase 3	NCT00746096	Sep 2008 → Sep 2009	primary dysmenorrhea	Nobelpharma	Completed	Met primary
Phase 3	NCT00569244	Dec 2007 → Dec 2009	primary dysmenorrhea	Bayer	Completed	Met primary
Phase 3	NCT00567164	Oct 2007 → Nov 2009	anovulation	Bayer	Completed	Met primary
Phase 3	NCT00455156	Dec 2006 → Jan 2009	—	Premier Research	Completed	No outcome recorded
Phase 3	NCT00391807	Nov 2006 → Aug 2008	—	Warner Chilcott	Completed	No outcome recorded
Phase 3	NCT00266032	Dec 2005 → Oct 2008	—	Bayer	Completed	Met primary
Phase 3	NCT00263341	Dec 2005 → Aug 2014	—	Population Council	Completed	Met primary
Phase 3	NCT00195559	Sep 2005 → Dec 2007	premenstrual dysphoric disorder	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00128934	Aug 2005 → Dec 2007	premenstrual tension	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	Mixed
Phase 3	NCT00117260	Jul 2005 → Jul 2007	—	Duramed Research	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT00161681	Jul 2005 → Aug 2006	premenstrual tension	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00193726	Jul 2005 → Mar 2012	breast cancer	Sudeep Gupta	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00212277	Feb 2005 → Sep 2006	dysmenorrhea	Nobelpharma	Completed	No outcome recorded
Phase 3	NCT00196365	Jan 2005 → Jul 2007	dysmenorrhea	Duramed Research	Completed	No outcome recorded
Phase 3	NCT00212342	Dec 2004 → Jan 2006	dysmenorrhea	Nobelpharma	Completed	No outcome recorded
Phase 3	NCT00185354	Nov 2004 → Apr 2006	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00229996	Jul 2004 → ?	endometriosis, pelvis syndrome	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	No outcome recorded
Phase 3	NCT00280657	Mar 2004 → May 2005	acne	Bayer	Completed	No outcome recorded
Phase 3	NCT00624130	Mar 2004 → Jun 2005	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00185484	Mar 2004 → Jan 2006	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00220324	Feb 2004 → Nov 2005	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00932321	Jan → Nov 2004	—	Warner Chilcott	Completed	No outcome recorded
Phase 3	NCT00185419	Nov 2003 → Mar 2006	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00196352	May 2003 → Nov 2006	—	Duramed Research	Completed	No outcome recorded
Phase 3	NCT00245921	Feb 2003 → Oct 2005	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00656981	Jan 2003 → Jun 2004	acne	Bayer	Completed	No outcome recorded
Phase 3	NCT00651469	Jan 2003 → Jul 2004	acne	Bayer	Completed	Met primary
Phase 3	NCT00367276	Dec 2002 → May 2004	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00236769	Nov 1997 → Oct 1999	—	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00236782	Oct 1997 → Mar 1999	—	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00000420	Jun 1997 → Aug 2003	systemic lupus erythematosus	NYU Langone Health	Completed	Met primary
Phase 3	NCT00236795	Jan 1997 → Mar 1999	—	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00248963	? → Oct 2004	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded

Phase 433 trials · 2 met primary · 1 missed
Phase 4	NCT06334315	Oct 2024 → May 2028 expected	—	Yale University	Recruiting	No outcome recorded
Phase 4	NCT06067256	Jul → Dec 2023	—	Italfarmaco	Unknown	No outcome recorded
Phase 4	NCT06324851	Jan → Aug 2023	endometrial polyp	University of Palermo	Completed	No outcome recorded
Phase 4	NCT06316206	Jan → Aug 2023	endometrial polyp	University of Palermo	Completed	No outcome recorded
Phase 4	NCT05002738	Sep 2021 → Nov 2022	—	University of Colorado, Denver	Completed	No outcome recorded
Phase 4	NCT04828824	Jun 2021 → Nov 2025	—	University of Colorado, Denver	Completed	No outcome recorded
Phase 4	NCT03077555	Jan 2017 → Feb 2018	anovulation	Mahidol University	Completed	No outcome recorded
Phase 4	NCT02710708	May 2016 → Jul 2018	—	Bayer	Completed	No outcome recorded
Phase 4	NCT02531321	Aug 2015 → Nov 2016	HIV infectious disease	University of Southern California	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT02352090	Apr 2015 → Dec 2018	—	Helsinki University Central Hospital	Completed	Missed primary
Phase 4	NCT02367846	Jan 2015 → Dec 2028 expected	bone development disease	Penn State University	Active not recruiting	No outcome recorded
Phase 4	NCT02367833	Jan 2015 → Dec 2017	bone disorder	Penn State University	Completed	No outcome recorded
Phase 4	NCT02210702	Jul 2014 → Jan 2015	postpartum depression	The Jones Institute	Unknown	No outcome recorded
Phase 4	NCT02237131	Apr 2014 → Apr 2015	dysmenorrhea, ovarian endometriosis, pelvis syndrome	University of Athens	Unknown	No outcome recorded
Phase 4	NCT02027337	Dec 2013 → Mar 2015	menstrual disorder, polycystic ovary syndrome	Tyumen State Medical Academy	Unknown	No outcome recorded
Phase 4	NCT01941134	Apr 2013 → Dec 2017	—	Johns Hopkins University	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT01757249	Jan → Nov 2013	infertility disorder	University of Oxford	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01608698	Jun 2012 → Jan 2016	—	Mahidol University	Unknown	Met primary
Phase 4	NCT01490190	Dec 2011 → Dec 2012	—	Organon and Co	Completed	No outcome recorded
Phase 4	NCT01448291	Oct 2011 → Oct 2012	bacterial vaginosis	Eastern Virginia Medical School	Unknown	No outcome recorded
Phase 4	NCT01360996	Aug 2011 → Feb 2015	polycystic ovary syndrome	Woman's	Completed	No outcome recorded
Phase 4	NCT01219101	Mar 2011 → Nov 2012	infertility disorder	Royan Institute	Completed	Met primary
Phase 4	NCT02342093	Jan 2011 → Jul 2013	hypertensive disorder	University of Sao Paulo	Completed	No outcome recorded
Phase 4	NCT01103518	Dec 2009 → Nov 2010	amenorrhea, dysmenorrhea	Fundação Educacional Serra dos Órgãos	Unknown	No outcome recorded
Phase 4	NCT01170390	Sep 2009 → Mar 2011	—	Oregon Health and Science University	Completed	No outcome recorded
Phase 4	NCT00826839	Jan 2009 → Sep 2010	infertility disorder	Weill Medical College of Cornell University	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT01174524	Jan → Nov 2008	—	Hospital Geral de Fortaleza	Completed	No outcome recorded
Phase 4	NCT00570440	Aug 2007 → Oct 2010	—	FHI 360	Completed	No outcome recorded
Phase 4	NCT00204451	Jul 2005 → Jun 2006	—	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT00261482	Jul 2003 → Dec 2004	—	Janssen Pharmaceutica N.V., Belgium	Completed	No outcome recorded
Phase 4	NCT00307632	Feb 2003 → Dec 2004	—	Janssen-Cilag Farmaceutica Ltda.	Completed	No outcome recorded
Phase 4	NCT00653016	Oct 2002 → Aug 2003	—	Janssen-Ortho Inc., Canada	Completed	No outcome recorded
Phase 4	NCT00732693	Feb 2002 → Nov 2006	primary ovarian failure	University of Edinburgh	Completed	Mixed

Phase not applicable27 trials · 3 missed
—	NCT07361263	Jan 2026 → Feb 2027 expected	diabetes insipidus	University Hospital, Basel, Switzerland	Recruiting	No outcome recorded
—	NCT07127458	Aug 2025 → Mar 2026	polycystic ovary syndrome	Ege University	Completed	No outcome recorded
—	NCT05233956	Oct 2023 → Dec 2026 expected	anemia	FHI 360	Active not recruiting	No outcome recorded
—	NCT04778514	Dec 2022 → Sep 2023	HIV infectious disease	Population Council	Completed	No outcome recorded
—	NCT05212389	Dec 2021 → Aug 2024	disease by molecular mechanism, major depressive disorder	Rigshospitalet, Denmark	Unknown	No outcome recorded
—	NCT02556411	Jun → Dec 2021	adenomyosis, chronic pain syndrome	University of Cagliari	Unknown	No outcome recorded
—	NCT04831151	Mar 2021 → Mar 2023	polycystic ovary syndrome	Inonu University	Unknown	No outcome recorded
—	NCT04539626	Oct 2020 → Apr 2023	COVID-19	CMN "20 de Noviembre"	Unknown	No outcome recorded
—	NCT04451746	Jun 2020 → Feb 2026	chronic venous insufficiency	Clinic of Phlebology and Laser Surgery, Chelyabinsk, Russia	Completed	No outcome recorded
—	NCT06560944	Jan 2020 → Jan 2024	—	University of Lincoln	Completed	No outcome recorded
—	NCT03043924	Sep 2017 → Apr 2022	polycystic ovary syndrome	University Hospital, Lille	Completed	No outcome recorded
—	NCT03230825	Sep 2017 → Sep 2018	—	Meir Medical Center	Unknown	No outcome recorded
—	NCT02865187	Feb 2017 → Mar 2020	polycystic ovary syndrome, sexual disorder	Wright State University	Completed	Missed primary
—	NCT02757469	May 2016 → May 2020	premature menopause	Navy General Hospital, Beijing	Unknown	No outcome recorded
—	NCT02529683	Apr 2014 → Aug 2015	—	Centers for Disease Control and Prevention	Completed	No outcome recorded
—	NCT01573377	Feb 2012 → Feb 2013	polycystic ovary syndrome	Chongqing Medical University	Completed	No outcome recorded
—	NCT01546454	Feb → Jun 2012	coronary artery disorder	Oregon Health and Science University	Completed	No outcome recorded
—	NCT01459445	Feb → Jun 2011	polycystic ovary syndrome	Iuliu Hatieganu University of Medicine and Pharmacy	Unknown	Mixed
—	NCT01414530	Apr 2010 → Jun 2014	premature menopause	Samsung Medical Center	Unknown	No outcome recorded
—	NCT00999479	Oct 2009 → Oct 2011	ovarian endometriosis	University of Oklahoma	Withdrawn	No outcome recorded Stop: Enrollment
—	NCT00633360	Feb 2008 → May 2011	depressive disorder, premenstrual tension	Massachusetts General Hospital	Completed	Missed primary
—	NCT00442689	Jul 2006 → Nov 2012	metabolic syndrome X, polycystic ovary syndrome	Northwestern University	Completed	No outcome recorded
—	NCT00237042	Oct 2005 → Jun 2010	temporomandibular joint disorder	University of Washington	Completed	Missed primary
—	NCT01372293	Jan 2005 → Jan 2008	polycystic ovary syndrome	Federal University of Rio Grande do Sul	Completed	No outcome recorded
—	NCT00350480	Apr 2003 → Jun 2005	menstrual disorder, uterine disorder	Kaiser Permanente	Completed	No outcome recorded
—	NCT00204438	Feb → Dec 2002	—	University of Saskatchewan	Completed	No outcome recorded
—	NCT00006133	Jun 2000 → ?	systemic lupus erythematosus	National Center for Research Resources (NCRR)	Completed	No outcome recorded

Comparator or background therapy108 trials
Phase 0	NCT02689843 Comparator	Feb → Nov 2018	polycystic ovary syndrome	Shiraz University of Medical Sciences	Completed	No outcome recorded
Phase 1	NCT07269327 Background	Nov 2025 → Mar 2026	infertility disorder	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	Completed	No outcome recorded
Phase 1	NCT05282940 Comparator	Feb → Mar 2022	—	Laboratorios Andromaco S.A.	Completed	No outcome recorded
Phase 1	NCT04713904 Comparator	Jan 2021	—	Laboratorios Andromaco S.A.	Completed	No outcome recorded
Phase 1	NCT04272008 Comparator	Mar 2020 → Jun 2021	—	TherapeuticsMD	Completed	No outcome recorded
Show all 108 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 25

Date	Issuer	Release
2026-07-29	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Regulatory Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch viatris.com ↗ Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system).
2026-02-12	Teva Canada	Regulatory Important: Voluntary Nationwide Recall PrSEASONIQUE Oral Contraceptive tevacanada.com ↗ Important: Voluntary Nationwide Recall PrSEASONIQUE Oral Contraceptive
2026-02-12	Teva Canada	Regulatory Important: Voluntary Nationwide Recall PrSEASONALE Extended‑Cycle Oral Contraceptive Tablets tevacanada.com ↗ Teva Canada Limited, with the knowledge of Health Canada, is initiating a nationwide voluntary Type I recall at the patient (consumer) level of one lot of PrSEASONALE (DIN 02296659) 3×91 Extended‑Cycle Oral Contraceptive Tablets.
2025-12-18	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Regulatory Viatris Provides Pipeline Update on Four Regulatory Milestones viatris.com ↗ The U.S. FDA has accepted for review the New Drug Application (NDA) for the Company's investigational low dose estrogen weekly patch (150 mcg norelgestromin and 17.5 mcg ethinyl estradiol) for contraception.
2025-06-04	Teva Canada	Regulatory Important Information - Voluntary Nationwide Recall SEASONIQUE tevacanada.com ↗ Toronto, Canada (June 4, 2025) - Teva Canada Limited, with the knowledge of Health Canada, is initiating a nationwide voluntary Type I to the Patient (Consumer) level recall of one (1) lot of prescription drug SEASONIQUE Oral Contraceptive 2x91 Extended-Cycle Tablet Dispenser
2025-05-08	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Results Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential viatris.com ↗ In this study, XULANE LO demonstrated a favorable efficacy and safety profile with no new safety concerns identified as well as a potential best-in-class patch performance profile.
2025-05-02	Teva Canada	Regulatory Important Information - Voluntary Nationwide Recall PrSEASONIQUE® tevacanada.com ↗ Teva Canada Limited, with the knowledge of Health Canada, is initiating a nationwide voluntary Type I to the Patient (Consumer) level recall of one (1) lot of prescription drug PrSEASONIQUE® Oral Contraception Tablets 2x91 Extended-Cycle Tablet Dispenser due to the possibility of missing tablets.
2024-02-16	Lupin Limited	Regulatory Lupin Receives Approval from U.S. FDA for Minzoya (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets) lupin.com ↗
2023-08-01	Lupin Limited	Regulatory Lupin Receives Approval from US FDA for Turqoz® (Norgestrel and Ethinyl Estradiol Tablets USP) lupin.com ↗ Mumbai, Baltimore, August 01, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Turqoz® (Norgestrel and Ethinyl Estradiol Tablets USP)0.3 mg/0.03 mg, to market a generic equivalent of Lo/Ovral-28 (Norgestrel and Ethinyl Estradiol Tablets)0.3 mg/0.03 mg of Wyeth Pharmaceuticals LLC.
2021-07-17	ViiV Healthcare	Results ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021 viivhealthcare.com ↗ Injection site reactions were more frequent in the CAB-LA arm.
2021-07-12	Merck Sharp & Dohme LLC	Results Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021 merck.com ↗ NNRTI MK-8507 Does Not Alter the Pharmacokinetics of the Combined Oral Contraceptive Levonorgestrel/Ethinyl Estradiol.
2019-07-09	AbbVie	Results Allergan Continues to Demonstrate Leadership in Migraine with 29 Presentations at the 2019 American Headache Society Annual Meeting abbvie.com ↗ Absence of Clinically Significant Drug Interactions With Coadministration of Atogepant and an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis.
2019-05-02	AbbVie	Results Allergan Continues to Display Leadership in Neurosciences with 29 Presentations at 2019 American Academy of Neurology Annual Meeting abbvie.com ↗ Absence of Clinically Significant Drug Interactions with Coadministration of Atogepant and an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis
2018-06-14	Lupin Limited	Regulatory Lupin receives FDA approval for generic Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg lupin.com ↗
2018-05-29	AbbVie	Regulatory Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules abbvie.com ↗ Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians sample pack, indicated for use by women to prevent pregnancy.
2017-12-14	Lupin Limited	Regulatory Lupin receives FDA approval for generic Safyral Tablets lupin.com ↗ Lupin announced that it has received final approval for its Tydemy
2016-11-01	Lupin Limited	Regulatory Lupin Receives FDA Approval for Generic Ortho-Cyclen® 28 Tablets lupin.com ↗ Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for Norgestimate and Ethinyl Estradiol Tablets USP, 0.25 mg/0.035 mg from the United States Food and Drug Administration (FDA) to market a generic version of Janssen Pharmaceuticals, Inc.’s Ortho-Cyclen® 28 Tablets (Norgestimate/Ethinyl Estradiol).
2016-01-08	Lupin Limited	Regulatory Lupin Receives FDA Approval for Generic Generess® Tablets lupin.com ↗
2016-01-06	Lupin Limited	Regulatory Lupin Launches Generic Ortho Tri-Cyclen® Lo Tablets lupin.com ↗ has launched its Tri-Lo-Marzia™ Tablets
2015-12-28	Lupin Limited	Regulatory Lupin Receives FDA Approval for Generic Generess® Tablets lupin.com ↗
2015-11-24	Lupin Limited	Regulatory Lupin Receives FDA Approvals for Generic Loestrin® Fe 1/20 and Loestrin®1.5/30 Tablets lupin.com ↗
2015-11-03	Lupin Limited	Regulatory Lupin Receives FDA Approval for Generic Loestrin®24 Fe Tablets lupin.com ↗ Lupin Limited (Lupin) announced today that it has received final approval for its Blisovi 24 Fe Tablets
2014-07-04	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Receives CHMP Positive Opinion for Seasonique® Extended-Regimen Contraceptive for Marketing Authorization in Several European Countries tevapharm.com ↗ The CHMP concluded that the benefits of Seasonique® outweigh its risks clearing the way for Seasonique®’s approval by local health authorities of the European Union (EU) Member States and launch in select countries throughout Europe by the end of 2014.
2013-03-29	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory FDA Approves New Drug Application (NDA) for Teva’s Quartette™ (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets for the Prevention of Pregnancy tevapharm.com ↗ Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Quartette™ (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets for the prevention of pregnancy.
2009-04-01	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Approval of Generic Yaz® Tablets tevapharm.com ↗ the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version for Bayer Healthcare Pharmaceuticals' oral contraceptive Yaz® (Drospirenone and Ethinyl Estradiol) Tablets.

All press releases naming this drug 32 releases

Date	Issuer	Release
2026-07-29	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch viatris.com ↗
2026-02-12	Teva Canada	Important: Voluntary Nationwide Recall PrSEASONIQUE Oral Contraceptive tevacanada.com ↗
2026-02-12	Teva Canada	Important: Voluntary Nationwide Recall PrSEASONALE Extended‑Cycle Oral Contraceptive Tablets tevacanada.com ↗
2025-12-18	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Viatris Provides Pipeline Update on Four Regulatory Milestones viatris.com ↗
2025-06-04	Teva Canada	Important Information - Voluntary Nationwide Recall SEASONIQUE tevacanada.com ↗
2025-05-08	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential viatris.com ↗
2025-05-02	Teva Canada	Important Information - Voluntary Nationwide Recall PrSEASONIQUE® tevacanada.com ↗
2025-01-13	Lupin Limited	Lupin Launches Minzoya TM (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets) in the United States lupin.com ↗
2024-04-15	Organon and Co	Organon’s HADLIMA™ (adalimumab-bwwd) and NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring) Added to Mark Cuban’s Cost Plus Drugs organon.com ↗
2024-02-16	Lupin Limited	Lupin Receives Approval from U.S. FDA for Minzoya (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets) lupin.com ↗
2023-12-01	Lupin Limited	Lupin Launches Turqoz®(Norgestrel and Ethinyl Estradiol) Tablets USP in the United States lupin.com ↗
2023-08-01	Lupin Limited	Lupin Receives Approval from US FDA for Turqoz® (Norgestrel and Ethinyl Estradiol Tablets USP) lupin.com ↗
2021-07-17	ViiV Healthcare	ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021 viivhealthcare.com ↗
2021-07-12	Merck Sharp & Dohme LLC	Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021 merck.com ↗
2021-01-14	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States tevapharm.com ↗
2019-07-09	AbbVie	Allergan Continues to Demonstrate Leadership in Migraine with 29 Presentations at the 2019 American Headache Society Annual Meeting abbvie.com ↗
2019-05-02	AbbVie	Allergan Continues to Display Leadership in Neurosciences with 29 Presentations at 2019 American Academy of Neurology Annual Meeting abbvie.com ↗
2018-08-27	Lupin Limited	Lupin launches generic Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg lupin.com ↗
2018-06-14	Lupin Limited	Lupin receives FDA approval for generic Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg lupin.com ↗
2018-05-29	AbbVie	Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules abbvie.com ↗
2017-12-14	Lupin Limited	Lupin receives FDA approval for generic Safyral Tablets lupin.com ↗
2017-03-16	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Launch of Authorized Generic of Minastrin® 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) in the United States tevapharm.com ↗
2016-11-01	Lupin Limited	Lupin Receives FDA Approval for Generic Ortho-Cyclen® 28 Tablets lupin.com ↗
2016-01-08	Lupin Limited	Lupin Receives FDA Approval for Generic Generess® Tablets lupin.com ↗
2016-01-06	Lupin Limited	Lupin Launches Generic Ortho Tri-Cyclen® Lo Tablets lupin.com ↗
2015-12-28	Lupin Limited	Lupin Receives FDA Approval for Generic Generess® Tablets lupin.com ↗
2015-11-24	Lupin Limited	Lupin Receives FDA Approvals for Generic Loestrin® Fe 1/20 and Loestrin®1.5/30 Tablets lupin.com ↗
2015-11-03	Lupin Limited	Lupin Receives FDA Approval for Generic Loestrin®24 Fe Tablets lupin.com ↗
2014-07-04	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Receives CHMP Positive Opinion for Seasonique® Extended-Regimen Contraceptive for Marketing Authorization in Several European Countries tevapharm.com ↗
2014-06-06	Merck Sharp & Dohme LLC	Merck Stands Behind the Safety Profile of NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring) merck.com ↗
2013-03-29	Teva Branded Pharmaceutical Products R&D, Inc.	FDA Approves New Drug Application (NDA) for Teva’s Quartette™ (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets for the Prevention of Pregnancy tevapharm.com ↗
2009-04-01	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Approval of Generic Yaz® Tablets tevapharm.com ↗

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 400 sources stand behind the page.

Field	Value	Cited text
Known as	ethinylestradiol	“The proposed study will use participants that currently use a specific preparation of oral contraceptive (30micrograms ethinyl estradiol and 150mg Levonorgestrel) and compare...” NCT06560944 ↗ 397 “Participants received a monophasic combined oral contraceptive pills containing 0.03 mg ethinyl estradiol and 3 mg drospirenone (Technospiron® 0.03/3 mg, Technopharm, Egypt),...” NCT07229209 ↗ “OCP containing 35 microgram ethinylestradiol and 2-milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21...” NCT03236740 ↗ “combined oral contraceptive pill (OCP) once daily for 21 days (Desogestrel 150 micrograms/ Ethinylestradiol 30 micrograms, tablets), starting from the first day of menses, then...” NCT05594186 ↗ “The purpose of the proposed project is to address the potential mechanism(s) by which oral ethinyl estradiol (EE) may negatively impair bone via "first pass" effects on the...” NCT02367833 ↗ “The aim of this study was to investigate the bleeding pattern and cycle control of a contraceptive patch containing 0.55 mg ethinyl estradiol (EE) and 2.1 mg gestodene (GSD)...” PMID 25453585 ↗ Oct 2014 “A study to assess the Pharmacokinetics (PK) of combined oral ethinyl estradiol (EE) and levonorgestrel (LNG) in healthy female participants of non-child-bearing potential, when...” NCT05505162 ↗ “An Open-Label, Single-Sequence, Crossover Study to Investigate the Interaction of Multiple Doses of BMS-986322 at Steady State and Multiple Doses of a Combined Oral Hormonal...” NCT05579574 ↗ “Single-arm, Open-label, Interventional Study to Observe the Safety and Efficacy Profile of the Combined Oral Contraceptive YAZ®, a 24-day Cyclic Regimen Containing Drospirenone...” NCT02710708 ↗ “Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10...” NCT01252186 ↗ “OBJECTIVE(S): To investigate the bleeding pattern and cycle control parameters of a contraceptive patch containing 0.55 mg ethinyl estradiol (EE) and 2.1 mg gestodene (GSD)...” PMID 25453582 ↗ Oct 2014 Show 387 more sources
Known as	EE	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03091595 ↗
Known as	EE2	“STUDY DESIGN: Thirty-three women were randomly assigned 1:1 to one of two OCs with 35-mcg ethinylestradiol (EE2) but different doses of NET - 1 or 0.4 mg.” PMID 22325110 ↗ Feb 2012
Known as	EE20	“20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP)” NCT00266032 ↗ 1 “Ethinyl Estradiol 20 (EE20)/DRSP (YAZ, BAY86-5300)” NCT02710708 ↗
Known as	ethinyloestradiol	“The volunteers received an oral single-dose of a combined contraceptive containing 30 μg ethinyloestradiol and 150 μg levonorgestrel on two occasions - once as such and once...” NCT02281448 ↗ 5 “An Open-label, Fixed-sequence and Two-part Study to Assess the Impact of Multiple Doses of Itraconazole on the Pharmacokinetics of AZD5004 in Healthy Participants and Multiple...” NCT06942936 ↗ “with a monophasic COC containing ethinyloestradiol/levonorgestrel (EE/LNG), with regard to their ability to reduce the frequency and intensity of headache and pelvic pain” PMID 23919857 ↗ Aug 2013 “7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules” NCT01384331 ↗ “ethinyl oestradiol 20ug plus gestodene 75ug during 6 cycles” NCT01372293 ↗ NCT01137708 ↗
Action	Inhibit	“Inhibition of Ovulation” NCT00915915 ↗
Modality	Small molecule	“14-day course of combined oral hormonal steroids” NCT01968135 ↗
Route	Oral	“oral contraceptives (triphasic ethinyl estradiol at a dose of 35 microg” PMID 16354891 ↗ Dec 2005